THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
Disease & Clinical Pharmacy Guides • 3-TIER LEARNING GUIDE

Type 2 Diabetes Mellitus (T2DM): Pathophysiology, ICMR/ADA Thresholds & Pharmacotherapy

Editorial Body: THE INDIAN PHARMACIST Editorial Reference Reading Time: 10 min read Published: 2026-01-15 Last Updated: 2026-11-08 Status: Evidence-Sourced Educational Guide

1. Level 1 — Quick Learning Overview & Core Definition

Quick Concept Summary: Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterised by peripheral insulin resistance (in skeletal muscle, liver, and adipose tissue) combined with progressive pancreatic beta-cell secretory decline. In clinical practice, oral Metformin remains the foundational first-line therapy alongside lifestyle modification, while SGLT2 inhibitors (Empagliflozin, Dapagliflozin) and GLP-1 receptor agonists provide proven cardiorenal protection regardless of baseline HbA1c.

2. Level 2 — Standard Study: Underlying Process & Major Classifications

Diagnostic thresholds established by the Indian Council of Medical Research (ICMR) and World Health Organization (WHO) define diabetes as Fasting Plasma Glucose (FPG) >= 126 mg/dL (7.0 mmol/L), 2-hour Post-Load Plasma Glucose >= 200 mg/dL (11.1 mmol/L) during a 75 g OGTT, or HbA1c >= 6.5% (48 mmol/mol). Prediabetes is defined by FPG 100–125 mg/dL or HbA1c 5.7%–6.4%.

Major Pharmacological & Scientific Classifications

  • Biguanides (Metformin Hydrochloride IP): Activates hepatic AMPK, suppresses hepatic gluconeogenesis, improves insulin sensitivity; weight-neutral and does not cause hypoglycaemia.
  • SGLT2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin): Block proximal tubular SGLT2 glucose reabsorption, lowering intraglomerular pressure and reducing heart failure hospitalisations.
  • Incretin Mimetics — GLP-1 Receptor Agonists (Semaglutide, Liraglutide) & DPP-4 Inhibitors (Sitagliptin, Vildagliptin, Teneligliptin): Enhance glucose-dependent insulin secretion and suppress glucagon.
  • Insulin Secretagogues — Sulfonylureas (Glimepiride, Gliclazide MR): Bind SUR1 subunit of pancreatic beta-cell K-ATP channels to trigger insulin exocytosis.
  • Thiazolidinediones (Pioglitazone): Activate nuclear PPAR-gamma receptors; contraindicated in NYHA Class III/IV heart failure.
  • Basal & Prandial Insulins: Regular Soluble Insulin, NPH, Insulin Glargine, Insulin Degludec, Insulin Aspart/Lispro.

3. Original Scientific Illustration (PLATE-8.11: 8.11 Diabetes Pharmacology & Insulin Action: Multi-Organ Targets of Metformin, SGLT2i, GLP-1 RA, DPP-4i & Insulins)

DIABETES PHARMACOLOGY: METFORMIN, SGLT2i, INCRETINS, SULFONYLUREAS & INSULIN 1. Liver: Biguanide (Metformin) • Activates hepatic AMPK & inhibits mitochondrial Complex I / mGPD • ↓ Hepatic Gluconeogenesis & ↑ Insulin sensitivity • Weight-neutral; zero intrinsic hypoglycaemia Contraindicated if eGFR < 30 mL/min; check B12 2. Kidney PCT: SGLT2 Inhibitors • Empagliflozin, Dapagliflozin, Canagliflozin • Block proximal tubule SGLT2 cotransporter • ↑ Glucosuria & Natriuresis → Restores TGF • Proven Heart Failure & CKD Protection Counsel: Genital mycotic infection, Euglycaemic DKA 3. Incretins & Beta-Cell Secretagogues • GLP-1 RAs (Semaglutide, Liraglutide) & DPP-4i (Sitagliptin, Vildagliptin): Glucose- dependent ↑ Insulin & ↓ Glucagon • Sulfonylureas (Glimepiride): Close SUR1/K-ATP channel → Ca2+ influx (Hypoglycaemia risk) INSULIN RECEPTOR SIGNALLING (RTK → IRS-1 → PI3K/Akt → GLUT4) & INSULIN PK PROFILES • Rapid-Acting Analogues (Aspart, Lispro, Glulisine): Onset 10–15 min | Peak 1–2 h | Duration 3–5 h (Inject immediately before meal) • Short-Acting Regular Soluble Insulin (Human Actrapid): Onset 30 min | Peak 2–4 h | Duration 6–8 h (Only insulin formulation safe for IV infusion in DKA) • Intermediate-Acting NPH (Isophane): Cloudy suspension; Onset 1–2 h | Peak 4–10 h | Duration 12–16 h • Long-Acting Basal Analogues (Glargine U100/U300, Degludec): Peakless 24–42 h basal coverage; NEVER administer Glargine IV; Cold-chain 2°C–8°C unopened.
Figure 8.11: Multi-organ mechanisms of antidiabetic drug classes and insulin receptor signalling across liver, kidney proximal tubule, pancreatic beta/alpha cells, gut incretins, and skeletal muscle.
Diagram Walkthrough: Type 2 Diabetes Mellitus involves progressive pancreatic beta-cell dysfunction, hepatic glucose overproduction, peripheral insulin resistance in skeletal muscle/adipose tissue, decreased incretin effect, and increased renal SGLT2 glucose reabsorption. (1) Metformin (First-line biguanide) activates hepatic AMP-activated protein kinase (AMPK) and inhibits mitochondrial Complex I, suppressing hepatic gluconeogenesis without causing hypoglycaemia or weight gain; it is contraindicated when eGFR < 30 mL/min/1.73m² due to lactic acidosis risk. (2) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin) inhibit Sodium-Glucose Cotransporter-2 in the S1 segment of the renal proximal tubule, promoting glucosuria, natriuresis, and tubuloglomerular feedback (reducing intraglomerular hypertension, slowing CKD progression, and reducing HFrEF/HFpEF hospitalisations). (3) GLP-1 Receptor Agonists (Semaglutide, Liraglutide) and DPP-4 Inhibitors (Sitagliptin, Vildagliptin, Teneligliptin) augment glucose-dependent insulin release and suppress glucagon. (4) Sulfonylureas (Glimepiride, Gliclazide) bind SUR1 on beta-cell K-ATP channels, causing depolarisation, Ca2+ influx, and insulin exocytosis.

4. Level 3 — Advanced Clinical, Pharmacokinetic & Regulatory Reference

Renal Dosing & Safety Governance: Metformin is cleared unchanged by renal glomerular filtration and OCT2/MATE tubular secretion. It is contraindicated when eGFR < 30 mL/min/1.73m²; initiation is not recommended when eGFR is 30–44 mL/min/1.73m², and the dose should be halved if eGFR falls below 45 mL/min/1.73m². Withhold Metformin 48 hours prior to iodinated contrast procedures in patients with impaired renal function to prevent lactic acidosis. Long-term Metformin therapy reduces Vitamin B12 absorption in the terminal ileum; monitor serum B12 periodically in patients with peripheral neuropathy or macrocytic anaemia.

5. Common Misunderstandings & Clinical Pitfalls

Common Misunderstanding: Assuming SGLT2 inhibitors are prescribed solely for HbA1c lowering. While their glycaemic efficacy diminishes when eGFR < 45 mL/min/1.73m², their natriuretic and tubuloglomerular feedback restoration benefits persist in slowing CKD progression and reducing HFrEF/HFpEF events.

6. Key Takeaways, Related Medicine Monographs & Calculators

Key Study & Practice Takeaways:
  • Target HbA1c < 7.0% for most non-pregnant adults; individualise to < 7.5%–8.0% in frail elderly patients or those prone to severe hypoglycaemia.
  • Prioritise SGLT2i or GLP-1 RA in patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease.
  • Teach every patient on Sulfonylureas or Insulin the 'Rule of 15' for acute hypoglycaemia (< 70 mg/dL): ingest 15 g fast-acting oral glucose and recheck capillary blood glucose after 15 minutes.

Related Medicine Monographs

💊 Metformin Hydrochloride [4.1] →💊 Glimepiride [4.2] →💊 Sitagliptin [4.4] →💊 Empagliflozin [4.8] → ⚖️ Compare Medicines →

Related Clinical Calculators

🧮 BMI Calculator (WHO & Indian Consensus) →🧮 Creatinine Clearance (Cockcroft-Gault) →🧮 Daily Divided Dose Calculator →

7. Authoritative Medical & Regulatory References

  1. Indian Pharmacopoeia Commission (IPC) & CDSCO: Indian Pharmacopoeia (IP 2022) & National List of Essential Medicines (NLEM 2022), Ministry of Health and Family Welfare, Government of India (https://ipc.gov.in/ & https://cdsco.gov.in/).
  2. NCBI Bookshelf / National Library of Medicine: StatPearls Pharmacology, Physiology & Clinical Therapeutics Compendia (https://www.ncbi.nlm.nih.gov/books/).
  3. DailyMed (US National Library of Medicine): Official FDA Prescribing Information & Clinical Pharmacology Labelling (US Jurisdiction Reference) (https://dailymed.nlm.nih.gov/dailymed/).
  4. MedlinePlus, NHS Health Information, Cleveland Clinic Health Library & National Institute on Aging (NIA): Structured patient education and clinical communication references (MedlinePlus • NHS • Cleveland Clinic • NIA).